Related Experiment Video
Updated: May 27, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Ruxolitinib as a novel therapeutic agent targeting mitochondrial function and chemo-resistance in nasopharyngeal
Lin Liu1, Yongbo Zhu1, Yunlong Zhang1
1Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei Province, China.
Abstract:
Chemo-resistance poses a significant obstacle in the effective treatment of nasopharyngeal carcinoma (NPC). To identify novel therapeutic strategies, we conducted high-throughput drug screening using a kinase-focused compound library on chemo-resistant NPC cells and normal human nasopharyngeal epithelial cells (HNECs). The screen identified several compounds with known anti-NPC activities, validating the robustness of the approach, and highlighted ruxolitinib, a Janus kinase (JAK) inhibitor, as a novel candidate. Ruxolitinib demonstrated selective cytotoxicity against NPC cells and exhibited strong synergy with 5-FU and cisplatin, significantly enhancing cytotoxicity in chemo-resistant cell lines. Mechanistic studies revealed that ruxolitinib disrupted mitochondrial bioenergetics through selectively inhibiting complex I activity, leading to reduced oxygen consumption rates, ATP production, and cell viability. In a chemo-resistant NPC mouse model, ruxolitinib delayed tumor growth, reduced tumor cell proliferation as indicated by decreased Ki67 staining, and extended overall survival without affecting body weight, demonstrating its efficacy and safety in vivo. These findings position ruxolitinib as a promising therapeutic agent for overcoming chemo-resistance in NPC, warranting further investigation into its clinical potential.
Insights
Ruxolitinib, a Janus kinase (JAK) inhibitor, shows promise in overcoming chemo-resistance in nasopharyngeal carcinoma (NPC). This drug selectively kills NPC cells and enhances chemotherapy effectiveness, offering a potential new treatment strategy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Chemo-resistance is a major challenge in nasopharyngeal carcinoma (NPC) treatment.
- Novel therapeutic strategies are needed to improve patient outcomes.
Purpose of the Study:
- To identify novel therapeutic agents for chemo-resistant NPC.
- To investigate the efficacy and mechanism of action of ruxolitinib in NPC.
Main Methods:
- High-throughput drug screening of a kinase-focused library on chemo-resistant NPC cells and normal human nasopharyngeal epithelial cells (HNECs).
- Evaluation of ruxolitinib's cytotoxicity, synergy with 5-FU and cisplatin, and effects on mitochondrial bioenergetics (Complex I activity, oxygen consumption, ATP production).
- In vivo assessment of ruxolitinib efficacy and safety in a chemo-resistant NPC mouse model.
Main Results:
- Ruxolitinib was identified as a novel candidate with selective cytotoxicity against NPC cells.
- Ruxolitinib demonstrated significant synergy with 5-FU and cisplatin in chemo-resistant NPC cell lines.
- Ruxolitinib inhibited mitochondrial Complex I, reducing cellular respiration and viability.
- In vivo, ruxolitinib delayed tumor growth, reduced proliferation, and extended survival in a chemo-resistant NPC mouse model without adverse effects on body weight.
Conclusions:
- Ruxolitinib is a promising therapeutic agent for overcoming chemo-resistance in NPC.
- Ruxolitinib's mechanism involves disruption of mitochondrial bioenergetics.
- Further clinical investigation of ruxolitinib for NPC treatment is warranted.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...